Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.

Herndon TM, Chen SS, Saba NS, Valdez J, Emson C, Gatmaitan M, Tian X, Hughes TE, Sun C, Arthur DC, Stetler-Stevenson M, Yuan CM, Niemann CU, Marti GE, Aue G, Soto S, Farooqui MZH, Herman SEM, Chiorazzi N, Wiestner A.

Leukemia. 2017 Jun;31(6):1340-1347. doi: 10.1038/leu.2017.11. Epub 2017 Jan 11.

2.

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.

Ahn IE, Underbayev C, Albitar A, Herman SE, Tian X, Maric I, Arthur DC, Wake L, Pittaluga S, Yuan CM, Stetler-Stevenson M, Soto S, Valdez J, Nierman P, Lotter J, Xi L, Raffeld M, Farooqui M, Albitar M, Wiestner A.

Blood. 2017 Mar 16;129(11):1469-1479. doi: 10.1182/blood-2016-06-719294. Epub 2017 Jan 3.

3.

Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.

Khoury P, Desmond R, Pabon A, Holland-Thomas N, Ware JM, Arthur DC, Kurlander R, Fay MP, Maric I, Klion AD.

Allergy. 2016 Jun;71(6):803-10. doi: 10.1111/all.12843. Epub 2016 Mar 2.

4.

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.

Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Mailankody S, Wu P, Morrison C, Costello R, Zhang Y, Burton D, Mulquin M, Zuchlinski D, Lamping L, Carpenter A, Wall Y, Carter G, Cunningham SC, Gounden V, Sissung TM, Peer C, Maric I, Calvo KR, Braylan R, Yuan C, Stetler-Stevenson M, Arthur DC, Kong KA, Weng L, Faham M, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Figg W, Landgren O.

JAMA Oncol. 2015 Sep;1(6):746-54. doi: 10.1001/jamaoncol.2015.2010.

PMID:
26181891
5.

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, Herman SE, Tian X, Marti G, Soto S, Hughes TE, Jones J, Lipsky A, Pittaluga S, Stetler-Stevenson M, Yuan C, Lee YS, Pedersen LB, Geisler CH, Calvo KR, Arthur DC, Maric I, Childs R, Young NS, Wiestner A.

Lancet Oncol. 2015 Feb;16(2):169-76. doi: 10.1016/S1470-2045(14)71182-9. Epub 2014 Dec 31.

6.

GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia.

Ganapathi KA, Townsley DM, Hsu AP, Arthur DC, Zerbe CS, Cuellar-Rodriguez J, Hickstein DD, Rosenzweig SD, Braylan RC, Young NS, Holland SM, Calvo KR.

Blood. 2015 Jan 1;125(1):56-70. doi: 10.1182/blood-2014-06-580340. Epub 2014 Oct 30.

7.

GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity.

Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, Arthur DC, Gu W, Gould CM, Brewer CC, Cowen EW, Freeman AF, Olivier KN, Uzel G, Zelazny AM, Daub JR, Spalding CD, Claypool RJ, Giri NK, Alter BP, Mace EM, Orange JS, Cuellar-Rodriguez J, Hickstein DD, Holland SM.

Blood. 2014 Feb 6;123(6):809-21. doi: 10.1182/blood-2013-07-515528. Epub 2013 Nov 13.

8.

Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia.

Shaffer BC, Modric M, Stetler-Stevenson M, Arthur DC, Steinberg SM, Liewehr DJ, Fowler DH, Gale RP, Bishop MR, Pavletic SZ.

Exp Hematol. 2013 Sep;41(9):772-8. doi: 10.1016/j.exphem.2013.04.015. Epub 2013 May 18.

9.

Bcl-2 level as a biomarker for 13q14 deletion in CLL.

Degheidy HA, Gadalla SM, Farooqui MZ, Abbasi F, Arthur DC, Bauer SR, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE.

Cytometry B Clin Cytom. 2013 Jul-Aug;84(4):237-47. doi: 10.1002/cyto.b.21090. Epub 2013 May 14.

10.

Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.

Shah NN, Bacher U, Fry T, Calvo KR, Stetler-Stevenson M, Arthur DC, Kurlander R, Baird K, Wise B, Giralt S, Bishop M, Hardy NM, Wayne AS.

Am J Hematol. 2012 Sep;87(9):916-22. doi: 10.1002/ajh.23174. Epub 2012 Apr 4. No abstract available.

11.

Therapy-related acute myelogenous leukemia in a hydroxyurea-treated patient with sickle cell anemia.

Taylor JG, Darbari DS, Maric I, McIver Z, Arthur DC.

Ann Intern Med. 2011 Nov 15;155(10):722-4. doi: 10.7326/0003-4819-155-10-201111150-00024. No abstract available. Erratum in: Ann Intern Med. 2012 Mar 6;156(5):404. Darari, Deepika S [corrected to Darbari, Deepika S]. Ann Intern Med. 2012 Jan 3;156(1 Pt 1):71. Darari, Deepika S [added]; Maric, Irina [added]; McIver, Zachariah [added]; Arthur, Diane C [added].

12.

Combined normal donor and CLL: Single tube ZAP-70 analysis.

Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE.

Cytometry B Clin Cytom. 2012 Mar;82(2):67-77. doi: 10.1002/cyto.b.20622. Epub 2011 Oct 26.

13.

Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications.

Calvo KR, Vinh DC, Maric I, Wang W, Noel P, Stetler-Stevenson M, Arthur DC, Raffeld M, Dutra A, Pak E, Myung K, Hsu AP, Hickstein DD, Pittaluga S, Holland SM.

Haematologica. 2011 Aug;96(8):1221-5. doi: 10.3324/haematol.2011.041152. Epub 2011 Apr 20.

14.

Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation.

Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE.

Cytometry B Clin Cytom. 2011 Sep;80(5):309-17. doi: 10.1002/cyto.b.20593. Epub 2011 Apr 6.

15.

Methodological comparison of two anti-ZAP-70 antibodies.

Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE.

Cytometry B Clin Cytom. 2011 Sep;80(5):300-8. doi: 10.1002/cyto.b.20591. Epub 2011 Apr 6.

16.

ProQ is an RNA chaperone that controls ProP levels in Escherichia coli.

Chaulk SG, Smith Frieday MN, Arthur DC, Culham DE, Edwards RA, Soo P, Frost LS, Keates RA, Glover JN, Wood JM.

Biochemistry. 2011 Apr 19;50(15):3095-106. doi: 10.1021/bi101683a. Epub 2011 Mar 23.

PMID:
21381725
17.

Structure of the periplasmic stress response protein CpxP.

Thede GL, Arthur DC, Edwards RA, Buelow DR, Wong JL, Raivio TL, Glover JN.

J Bacteriol. 2011 May;193(9):2149-57. doi: 10.1128/JB.01296-10. Epub 2011 Feb 11.

18.

Mapping interactions between the RNA chaperone FinO and its RNA targets.

Arthur DC, Edwards RA, Tsutakawa S, Tainer JA, Frost LS, Glover JN.

Nucleic Acids Res. 2011 May;39(10):4450-63. doi: 10.1093/nar/gkr025. Epub 2011 Jan 28.

19.

N. meningitidis 1681 is a member of the FinO family of RNA chaperones.

Chaulk S, Lu J, Tan K, Arthur DC, Edwards RA, Frost LS, Joachimiak A, Glover JN.

RNA Biol. 2010 Nov-Dec;7(6):812-9. Epub 2010 Nov 1.

20.

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, Gibellini F, Njuguna N, Lee E, Stennett L, Raghavachari N, Liu P, McCoy JP, Raffeld M, Stetler-Stevenson M, Yuan C, Sherry R, Arthur DC, Maric I, White T, Marti GE, Munson P, Wilson WH, Wiestner A.

Blood. 2011 Jan 13;117(2):563-74. doi: 10.1182/blood-2010-05-284984. Epub 2010 Oct 12.

21.

Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia.

Raygada M, Arthur DC, Wayne AS, Rennert OM, Toretsky JA, Stratakis CA.

Pediatr Blood Cancer. 2010 Jan;54(1):173-5. doi: 10.1002/pbc.22297.

22.

Hypocalcemia in a patient with osteosarcoma and 22q11.2 deletion syndrome.

Mussai FJ, Cunningham LC, Rezvani G, Stratakis CA, Reynolds JC, Nesterova G, Henshaw RM, Levine JE, Helman LJ, Arthur DC, Kim SY.

J Pediatr Hematol Oncol. 2008 Aug;30(8):612-7. doi: 10.1097/MPH.0b013e318168f072.

23.

Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience.

Mrózek K, Carroll AJ, Maharry K, Rao KW, Patil SR, Pettenati MJ, Watson MS, Arthur DC, Tantravahi R, Heerema NA, Koduru PR, Block AW, Qumsiyeh MB, Edwards CG, Sterling LJ, Holland KB, Bloomfield CD.

Int J Oncol. 2008 Aug;33(2):239-44.

24.

Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion.

Lahortiga I, Akin C, Cools J, Wilson TM, Mentens N, Arthur DC, Maric I, Noel P, Kocabas C, Marynen P, Lessin LS, Wlodarska I, Robyn J, Metcalfe DD.

Haematologica. 2008 Jan;93(1):49-56. doi: 10.3324/haematol.11836.

25.

Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia.

Ng D, Toure O, Wei MH, Arthur DC, Abbasi F, Fontaine L, Marti GE, Fraumeni JF Jr, Goldin LR, Caporaso N, Toro JR.

Blood. 2007 Feb 1;109(3):916-25. Epub 2006 Oct 17.

26.
27.

Doctors and torture.

Winkenwerder W Jr, Kiley KC, Arthur DC, Taylor GP Jr, Porr DR.

N Engl J Med. 2004 Oct 7;351(15):1571-4; author reply 1571-4. No abstract available.

PMID:
15473017
28.

Emergency physicians in the United States Military.

Arthur DC.

Ann Emerg Med. 2004 May;43(5):672; author reply 672-3. No abstract available.

PMID:
15259156
29.

Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.

Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC, Mitchell JB, Marti GE, Fowler DH, Wilson WH, Staudt LM.

Blood. 2004 Sep 1;104(5):1428-34. Epub 2004 May 11.

30.

Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.

Byrd JC, Ruppert AS, Mrózek K, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Stamberg J, Koduru PR, Moore JO, Mayer RJ, Davey FR, Larson RA, Bloomfield CD.

J Clin Oncol. 2004 Mar 15;22(6):1087-94.

PMID:
15020610
31.

FinO is an RNA chaperone that facilitates sense-antisense RNA interactions.

Arthur DC, Ghetu AF, Gubbins MJ, Edwards RA, Frost LS, Glover JN.

EMBO J. 2003 Dec 1;22(23):6346-55.

32.

Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children's Cancer Group.

Dusenbery KE, Howells WB, Arthur DC, Alonzo T, Lee JW, Kobrinsky N, Barnard DR, Wells RJ, Buckley JD, Lange BJ, Woods WG.

J Pediatr Hematol Oncol. 2003 Oct;25(10):760-8.

PMID:
14528097
33.

Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor.

Debelenko LV, Arthur DC, Pack SD, Helman LJ, Schrump DS, Tsokos M.

Lab Invest. 2003 Sep;83(9):1255-65.

PMID:
13679433
34.

Characterizing the structural features of RNA/RNA interactions of the F-plasmid FinOP fertility inhibition system.

Gubbins MJ, Arthur DC, Ghetu AF, Glover JN, Frost LS.

J Biol Chem. 2003 Jul 25;278(30):27663-71. Epub 2003 May 14.

35.

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.

Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM.

Blood. 2003 Jun 15;101(12):4944-51. Epub 2003 Feb 20.

36.

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD; Cancer and Leukemia Group B (CALGB 8461).

Blood. 2002 Dec 15;100(13):4325-36. Epub 2002 Aug 1.

37.

Failure: lessons for health care leaders.

Chaffee MW, Arthur DC.

Nurs Econ. 2002 Sep-Oct;20(5):225-8, 231. Review. No abstract available.

PMID:
12382540
38.

Probing FinO-FinP RNA interactions by site-directed protein-RNA crosslinking and gelFRET.

Ghetu AF, Arthur DC, Kerppola TK, Glover JN.

RNA. 2002 Jun;8(6):816-23.

39.

Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213.

Wells RJ, Arthur DC, Srivastava A, Heerema NA, Le Beau M, Alonzo TA, Buxton AB, Woods WG, Howells WB, Benjamin DR, Betcher DL, Buckley JD, Feig SA, Kim T, Odom LF, Ruymann FB, Smithson WA, Tannous R, Whitt JK, Wolff L, Tjoa T, Lampkin BC.

Leukemia. 2002 Apr;16(4):601-7.

40.

Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group.

Woods WG, Barnard DR, Alonzo TA, Buckley JD, Kobrinsky N, Arthur DC, Sanders J, Neudorf S, Gold S, Lange BJ.

J Clin Oncol. 2002 Jan 15;20(2):434-40.

PMID:
11786571
41.

Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia.

Magnusson MK, Meade KE, Brown KE, Arthur DC, Krueger LA, Barrett AJ, Dunbar CE.

Blood. 2001 Oct 15;98(8):2518-25.

42.

Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome.

Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, Venzon D, Rick ME.

Blood. 2001 Aug 15;98(4):979-87.

43.

A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission.

Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, Dusenbery K, DeSwarte J, Arthur DC, Lange BJ, Kobrinsky NL; Children's Cancer Group.

Blood. 2001 Jan 1;97(1):56-62.

44.

Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group.

Heerema NA, Sather HN, Sensel MG, Liu-Mares W, Lange BJ, Bostrom BC, Nachman JB, Steinherz PG, Hutchinson R, Gaynon PS, Arthur DC, Uckun FM.

Blood. 1999 Sep 1;94(5):1537-44.

45.

Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t(4;11) - a report of the Children's Cancer Group.

Heerema NA, Sather HN, Ge J, Arthur DC, Hilden JM, Trigg ME, Reaman GH.

Leukemia. 1999 May;13(5):679-86.

PMID:
10374870
46.

Chromosome abnormalities of eighty-one pediatric germ cell tumors: sex-, age-, site-, and histopathology-related differences--a Children's Cancer Group study.

Bussey KJ, Lawce HJ, Olson SB, Arthur DC, Kalousek DK, Krailo M, Giller R, Heifetz S, Womer R, Magenis RE.

Genes Chromosomes Cancer. 1999 Jun;25(2):134-46.

PMID:
10337997
47.

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ.

Cancer Res. 1998 Sep 15;58(18):4173-9.

48.

Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study.

Heinonen K, Mrózek K, Lawrence D, Arthur DC, Pettenati MJ, Stamberg J, Qumsiyeh MB, Verma RS, MacCallum J, Schiffer CA, Bloomfield CD.

Br J Haematol. 1998 Jun;101(3):513-20.

PMID:
9633896
49.

Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461.

Byrd JC, Lawrence D, Arthur DC, Pettenati MJ, Tantravahi R, Qumsiyeh M, Stamberg J, Davey FR, Schiffer CA, Bloomfield CD.

Clin Cancer Res. 1998 May;4(5):1235-41.

50.

Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children's Cancer Group.

Heerema NA, Sather HN, Sensel MG, Kraft P, Nachman JB, Steinherz PG, Lange BJ, Hutchinson RS, Reaman GH, Trigg ME, Arthur DC, Gaynon PS, Uckun FM.

J Clin Oncol. 1998 Apr;16(4):1270-8.

PMID:
9552025

Supplemental Content

Loading ...
Support Center